Dr. Reddy's (RDY) partners with Shanghai Henlius Biotech to develop and market biosimilar versions of J&J's (JNJ) multiple ...

One of the biggest risk is probably aging, myeloma is more common as people grow older. So the median age at which patients get diagnosed with myeloma is about 68/69 years. So it's still predominantly ...

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

Our Lady of the Lake Cancer Institute is celebrating after successfully completing a bone marrow transplant so rare it has ...

Dr. Reddy’s to develop and commercialize biosimilar candidate for Johnson & Johnson’s Darzalex drugs with Shanghai Henlius Biotech.

Bristol-Myers Squibb (SMY) stock falls as its Q4 2024 results beat Street forecasts, but its 2025 outlook fell short of ...

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies across multiple areas of the business,” its CFO told analysts on a conference ...

Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe: Our Bureau, Bengaluru Thursday, February 6, 2025, 17:20 Hrs [IST] Dr Reddy’s La ...

CAMBRIDGE, Mass. - 2seventy bio, Inc. (NASDAQ:TSVT), currently trading at $2.74 and showing significant volatility according to InvestingPro data, in partnership with Bristol Myers Squibb (BMS), ...

HYDERABAD: Dr Reddy’s Laboratories SA, the wholly-owned Swiss subsidiary of Hyderabad-based pharma biggie Dr Reddy’s ...

CAMBRIDGE, Mass., February 06, 2025--2seventy bio, Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...